Successful Management of Fetal Supraventricular Tachycardia With Flecainide in a Case Complicated by Early Hydrops Fetalis: A Case Report Authors: Amirabbas Faridpour, Yazdan Ghandi, Alireza Golbabaei Published: 2026 ABSTRACT ABSTRACTFetal arrhythmia that can lead to hydrops fetalis and fetal heart failure if untreated. This case report describes the successful treatment of a fetus with SVT at 26 weeks of gestation using flecainide. A 37‐year‐old gravida 3, para 2 woman was diagnosed with fetal SVT during a routine ultrasound, which also revealed mild pleural effusion, pericardial effusion, and ascites, raising concerns for hydrops fetalis. A fetal echocardiogram confirmed a heart rate of 250–300 beats per minute with preserved cardiac function. The mother was started on oral flecainide at 100 mg twice daily, which was increased to 150 mg twice daily after 3 days due to persistent fetal tachycardia. Within 24 h of the dosage adjustment, the fetal heart rate normalized to 120–130 beats per minute, and the hydrops resolved by the third week of treatment. The mother delivered a healthy baby at 39 weeks, and the infant has remained free of SVT episodes to date. This case demonstrates the efficacy and safety of flecainide in treating fetal SVT, particularly in cases complicated by early hydrops.Keywords: case report, fetal supraventricular tachycardia, flecainide Clinical Key Message Flecainide is a highly effective antiarrhythmic for fetal SVT, particularly when first‐line treatments fail or hydrops is present. In this case, it successfully restored the fetal heart rate within 24 h of dosage adjustment. Resolution of hydrops fetalis (mild pleural effusion, pericardial effusion, and ascites) within 3 weeks of flecainide treatment highlights its effectiveness in reversing early signs of fetal compromise. Background Fetal tachyarrhythmia occurs in about 1% of all pregnancies and is potentially life‐threatening [1]. Fetal supraventricular tachycardia (SVT) is the most common fetal arrhythmia, occurring in approximately 0.4%–0.6% of pregnancies [2]. It is characterized by a sustained rapid heart rate, typically exceeding 180 beats per minute, which, if left untreated, can result in significant complications such as hydrops fetalis, heart failure, and even intrauterine fetal demise (IUFD) [3, 4]. Fetal tachycardias frequently go undiagnosed until the onset of hydrops, which can lead to severe outcomes, including neurological complications and death [5]. Fetal hydrops is linked to a 35% intrauterine mortality rate, even with treatment, in contrast to a mortality rate of 0% to 4% in fetuses without hydrops [6]. The primary treatment strategy for fetal SVT involves the administration of antiarrhythmic medications to the mother, which cross the placenta and act on the fetal heart. Digoxin, flecainide, sotalol, amiodarone, and other antiarrhythmic agents have been found to be effective in the treatment of fetal SVT in multiple studies [7, 8]. In this report, we present a case of fetal SVT diagnosed at 26 weeks of gestation, which was successfully treated with flecainide. This case highlights the efficacy and safety of flecainide as a therapeutic option for fetal SVT, particularly in cases where hydrops is present, and early control of the arrhythmia is essential to prevent further fetal compromise. Case Presentation and Investigations A 37‐year‐old gravida 3, para 2 (G3P2) woman at 26 weeks of gestation presented to the gynecology clinic for a routine ultrasound. Her obstetric history includes one normal vaginal delivery and one Cesarean section, both without complications. She has no significant gynecological or medical history, does not smoke or consume alcohol, and has no known allergies. Her medication regimen is limited to prenatal supplements, including daily folic acid, iron, calcium, and vitamin D. Throughout her pregnancy, she has experienced normal periodic visits, without reports of reduced fetal movements or other concerning symptoms. During her most recent visit, vital signs were stable, with a blood pressure of 110/75 mmHg and a pulse rate of 72 beats per minute; she exhibited no fever or signs of distress and reported no excessive caffeine intake. Laboratory tests, including complete blood count, renal function, liver enzymes, electrolytes, and thyroid function, were all within normal ranges. The routine fetal ultrasound revealed a singleton male fetus with cephalic presentation, demonstrating biometry—biparietal diameter, head circumference, abdominal circumference, and femur length—appropriate for his gestational age. Amniotic fluid levels were normal, and the placenta was located anteriorly with no abnormalities detected. The routine ultrasound did not reveal fetal heart rate abnormalities. However, the ultrasound incidentally indicated mild pleural effusion, pericardial effusion, and ascites, raising concerns for hydrops fetalis (Figure 1). Axial view of the fetal abdomen demonstrating significant ascites, as indicated by the yellow arrows. Consequently, the patient was referred to a pediatric cardiologist for further evaluation, where a fetal echocardiogram was performed. The echocardiogram revealed a heart rate ranging from 250–300 beats per minute with 1:1 conduction, consistent with persistent supraventricular tachycardia (SVT). Also, the echocardiogram showed mild pericardial effusion (Figure 2). Importantly, there were no signs of cardiomegaly or indicating stable cardiac function. Diastolic function assessments showed a mitral valve E/A ratio of 0.62 and a tricuspid valve E/A ratio of 0.63, suggesting preserved diastolic function despite the elevated heart rate. The left ventricular myocardial performance index (LVMPI) was calculated at 0.35, falling within acceptable limits and indicating preserved systolic and diastolic function. Overall, while the fetal echocardiogram demonstrated significant tachycardia, it did not reveal any structural heart abnormalities or dysfunction, allowing for a targeted approach to management. Echocardiogram of the Fetus Prior to Intervention. (A) The Doppler spectral analysis in the left ventricular outflow tract (LVOT) reveals marked tachycardia, characterized by a 1:1 atrioventricular conduction pattern. This indicates a rapid heart rate consistent with supraventricular tachycardia. (B) The axial view of the fetal thoracic cavity demonstrates a small pericardial effusion (indicated by the red arrow) and pleural effusions (highlighted by the yellow arrows). A: Atrial Contraction, V: Ventricular Contraction, PE: Pericardial Effusion, PLE: Pleural Effusion. Treatment and Outcome Upon diagnosing fetal supraventricular tachycardia (SVT), the mother was admitted to the hospital for treatment. A cardiologist evaluated her to rule out any preexisting cardiac conditions, particularly arrhythmias. Once her cardiac health was confirmed, treatment with flecainide was initiated at a dosage of 100 mg twice daily, with continuous cardiac monitoring during her hospitalization. After 3 days, as the treatment was ineffective, the fetal SVT persisted and the flecainide dosage was increased to 150 mg twice daily. This adjustment successfully stabilized the fetal heart rate within 24 h, bringing it to approximately 120–130 beats per minute, as confirmed by echocardiogram, which showed normal conduction (Figure 3). Echocardiogram of the fetus following successful treatment. (A) Doppler spectral analysis of a major artery in the fetal heart demonstrates a significant decrease in heart rate, indicating a positive response to treatment. (B) Doppler spectral imaging of the left ventricular outflow tract (LVOT) reveals a normal sinus rhythm, suggesting improved cardiac function and stability. A: Atrial contraction, V: Ventricular contraction. The mother was discharged after an additional 24 h of stable fetal rhythm without complications. She continued outpatient treatment with the same flecainide dosage. Weekly visits with a pediatric cardiologist were scheduled until the pleural effusion, pericardial effusion, and fetal ascites resolved by the third week of treatment (Figure 4). The medication dosage was subsequently reduced to 100 mg twice daily, which was maintained until delivery. Resolution of Hydrops Fetalis after successful treatment. (A) Axial view of the thoracic cavity demonstrating the resolution of pericardial effusion (red arrow) and pleural effusion (red arrow), indicating improved fluid status and overall fetal health. (B) Axial view of the fetal abdomen illustrating the absence of ascites, as indicated by the yellow arrows, further confirming the resolution of hydrops fetalis. H: Heart. The mother delivered a healthy baby at 39 weeks of gestation. Notably, the infant has not experienced any episodes of SVT to date and is currently 6 months old. The neonate did not require any postnatal anti‐arrhythmic therapy and has remained in normal sinus rhythm without recurrence of SVT. Discussion Sustained fetal tachyarrhythmias are associated with considerable mortality and morbidity, though they occur infrequently, with a prevalence of about 1 in 1000 pregnancies [8]. Fetal SVT is the most common type of fetal tachyarrhythmia. If left untreated, SVT can result in serious complications, including fetal hydrops and intrauterine fetal demise (IUFD), due to prolonged cardiac dysfunction and heart failure [9]. Early detection and intervention are essential for enhancing fetal outcomes, particularly in cases where signs of hydrops fetalis are evident, as illustrated in our case. The use of antiarrhythmic medications, particularly transplacentally administered drugs, is the main treatment strategy for fetal SVT. The choice of drug and treatment regimen depends on several factors, including the gestational age of the fetus, the presence of hydrops fetalis, maternal health, and the overall stability of the fetal cardiac function [10]. Digoxin has traditionally been regarded as the first‐line treatment for fetal SVT [11]. It has a long history of use in managing various arrhythmias and offers a positive inotropic effect, making it particularly beneficial in cases of impaired systolic function [12]. In neonates with atrioventricular reentry tachycardia, digoxin has been employed to prevent recurrence; however, flecainide has been shown to be a more effective alternative [8, 13]. Despite the rationale for using the most effective agent available for treating fetal tachycardia, there has been some reluctance to utilize flecainide due to safety concerns [11]. Flecainide, a class Ic antiarrhythmic agent, has been widely used in managing fetal SVT due to its ability to slow conduction through the atria and ventricles without significantly affecting myocardial contractility. Flecainide works by inhibiting sodium channels in cardiac cells, leading to a decrease in conduction velocity and an increase in the refractory period [14]. This mechanism is particularly beneficial in reentrant tachycardias, such as SVT, where abnormal electrical pathways within the heart perpetuate rapid heart rates. By inhibiting these pathways, flecainide restores normal conduction and rhythm. In this case, flecainide was chosen as the first‐line treatment based on the stable hemodynamic profile of the fetus, the absence of structural heart disease, and the preserved diastolic function observed on fetal echocardiography. The initial dose of 100 mg twice daily was insufficient to control the fetal SVT, but after adjusting the dose to 150 mg twice daily, the fetal heart rate normalized within 24 h. This rapid response underscores the importance of dose titration in cases where the initial treatment is ineffective. Treatment Challenges and Monitoring The management of fetal SVT requires careful monitoring of both the fetus and the mother. Continuous cardiac monitoring is necessary during the initiation of antiarrhythmic therapy to assess the fetal response and ensure maternal safety. Flecainide, although effective, carries potential risks, including proarrhythmia and conduction abnormalities [15]. In this case, the maternal evaluation ruled out any preexisting cardiac conditions, ensuring that flecainide could be administered safely. In our case, given the high fetal heart rate and the presence of hydrops fetalis, prompt intervention was critical to prevent progression to heart failure. While fetal SVT can be associated with a poor prognosis if hydrops develops, the early detection in this case allowed for successful pharmacologic management before irreversible cardiac damage occurred. The resolution of hydrops within 3 weeks of treatment with flecainide highlights the effectiveness of the therapy in reversing the hemodynamic consequences of sustained tachycardia. Comparative Effectiveness and Safety The high maternal and fetal bioavailability of flecainide, even in cases of fetal hydrops, position it as a promising therapeutic option for the indirect management of fetal SVT. Various studies have demonstrated the successful use of flecainide in treating fetal SVT, achieving restoration of sinus rhythm in 43%–85% of hydropic fetuses and in all non‐hydropic fetuses [16]. Other antiarrhythmic agents, such as digoxin and sotalol, are also used in fetal SVT management; however, flecainide is often preferred in more severe cases or when initial treatment with digoxin fails. In cases of fetal hydrops, flecainide has a superior ability to penetrate the placental barrier and achieve therapeutic concentrations in the fetus compared to digoxin, which has limited efficacy in such settings [12]. The favorable outcome in this case, with the resolution of fetal tachycardia and hydrops followed by the delivery of a healthy baby at term, supports the use of flecainide as a safe and effective treatment for fetal SVT. Regular fetal echocardiography and close follow‐up were essential in ensuring the continued stability of the fetal heart rate and the gradual reduction in the signs of hydrops. Maternal Considerations and Management of Flecainide‐Related Complications Although flecainide is generally well‐tolerated [17], its use during pregnancy requires careful maternal monitoring due to potential complications. Common side effects include gastrointestinal symptoms such as nausea and constipation, as well as dizziness or visual disturbances [17, 18]. More serious concerns include proarrhythmic effects or conduction abnormalities, especially in women with underlying cardiac disease. Therefore, baseline maternal ECG and echocardiography are essential before initiating therapy, and serial ECG monitoring is recommended during treatment [18]. In cases of mild side effects, dose adjustments or dividing doses can help improve tolerability. If significant QRS prolongation or conduction block occurs, flecainide should be reduced or discontinued [17]. For women unable to tolerate flecainide, alternatives such as digoxin, sotalol, or—rarely—amiodarone may be considered [18]. A multidisciplinary approach involving maternal–fetal medicine and pediatric cardiology is essential to ensure both maternal safety and effective fetal rhythm control. Long‐Term Considerations Postnatal follow‐up is essential for infants treated for fetal SVT as recurrence can occur in the neonatal period or infancy. In this case, the infant remained free of SVT episodes up to 6 months of age, suggesting that the intrauterine treatment was both effective and durable. Flecainide's ability to prevent recurrence in the short term is well documented, although long‐term outcomes vary depending on the underlying cause of the arrhythmia. Conclusion The successful management of fetal SVT with flecainide in this case demonstrates the importance of timely diagnosis, appropriate drug selection, and vigilant monitoring during pregnancy. Flecainide, with its favorable pharmacokinetic properties and efficacy in resolving tachyarrhythmias, proved to be an excellent treatment choice, resulting in the normalization of fetal heart rate and resolution of hydrops. This case adds to the growing body of evidence supporting flecainide as a first‐line treatment for fetal SVT, particularly in the presence of mild hydrops. Author Contributions Amirabbas Faridpour: conceptualization, data curation, investigation, methodology, resources, writing – original draft, writing – review and editing. Yazdan Ghandi: conceptualization, investigation, methodology, resources, supervision, validation, writing – review and editing. Alireza Golbabaei: conceptualization, investigation, methodology, project administration, resources, supervision, validation, writing – review and editing. Funding This article was not funded by any individual or organization. Ethics Statement A written informed consent was obtained from the participant. Authors confirm that all methods were performed in accordance with institutional ethical standards and the Declaration of Helsinki. Consent A written informed consent for publicly reporting the information of the condition was obtained from the participant. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors have nothing to report. Not applicable. Data Availability Statement All data are available from the corresponding author on reasonable request. References Associated Data Data Availability Statement All data are available from the corresponding author on reasonable request.